Hostname: page-component-68c7f8b79f-cf4j5 Total loading time: 0 Render date: 2026-01-16T00:15:11.886Z Has data issue: false hasContentIssue false

Reviewer Comment on Injar et al. “Screening and management of depression and anxiety in people with epilepsy: A quality improvement study”

Published online by Cambridge University Press:  06 January 2026

Jonah Fox*
Affiliation:
Vanderbilt University Medical Center, Nashville, TN, USA
*
Corresponding author: Jonah Fox; Email: jonah.fox@vumc.org
Rights & Permissions [Opens in a new window]

Abstract

Information

Type
Reviewer Comment
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

The inclusion of psychological manifestations in the International League Against Epilepsy’s (ILAE) conceptual definition of epilepsy may suggest their relevance for diagnostic and therapeutic considerations. Reference Fisher, Acevedo and Arzimanoglou1 Accordingly, both the ILAE and American Academy of Neurology recommend that depression and anxiety screening be performed routinely on all patients with epilepsy. Reference Kerr, Mensah and Besag2,Reference Patel, Baca and Franklin3 However, previous studies have suggested that screening is often not performed and many epilepsy patients with psychiatric comorbidities remain untreated. Reference Ajinkya, Fox and Lekoubou4 This is a significant concern because psychiatric comorbidities are among the most important predictors of quality of life in patients with epilepsy. Reference Boylan, Flint, Labovitz, Jackson, Starner and Devinsky5

Injar and colleagues report on their experience administering screening instruments for depression and anxiety in their epilepsy group over several years. Reference Injar, Keezer, Lapalme-Remis, Chamelian, Bou Assi and Nguyen6 Expectedly, a little more than one-third of patients screened positive on at least one questionnaire. However, fewer than half of these patients received an intervention. Most were referred to a mental health professional, but only two patients were prescribed a new antidepressant medication. Twenty-nine percent had their anti-seizure medication adjusted, which included the introduction of a new anti-seizure medication in 41% of cases. For example, several patients had lamotrigine added, although this is not the first-line treatment for depression or anxiety.

These findings suggest that although the implementation of screening instruments may help identify patients with depression or anxiety, many epileptologists may feel uncomfortable or unsure about how to treat these conditions. As a field, we must do better – not only to increase awareness and diagnosis of psychiatric comorbidities in epilepsy but also to improve education on their management.

Competing interests

None.

References

Fisher, RS, Acevedo, C, Arzimanoglou, A, et al. ILAE official report: A practical clinical definition of epilepsy. Epilepsia. 2014;55:475482.10.1111/epi.12550CrossRefGoogle ScholarPubMed
Kerr, MP, Mensah, S, Besag, F, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia. 2011;52:21332138.CrossRefGoogle ScholarPubMed
Patel, AD, Baca, C, Franklin, G, et al. Quality improvement in neurology: Epilepsy Quality Measurement Set 2017 update. Neurol. 2018;91:829836.10.1212/WNL.0000000000006425CrossRefGoogle ScholarPubMed
Ajinkya, S, Fox, J, Lekoubou, A. Trends in prevalence and treatment of depressive symptoms in adult patients with epilepsy in the United States. Epilepsy Behav. 2020;105:106973.10.1016/j.yebeh.2020.106973CrossRefGoogle ScholarPubMed
Boylan, LS, Flint, LA, Labovitz, DL, Jackson, SC, Starner, K, Devinsky, O. Depression but not seizure frequency predicts quality of life in treatment-resistant epilepsy. Neurol. 2004;62:258261.10.1212/01.WNL.0000103282.62353.85CrossRefGoogle Scholar
Injar, I, Keezer, M, Lapalme-Remis, S, Chamelian, L, Bou Assi, E, Nguyen, DK. Screening and management of depression and anxiety in people with epilepsy: A quality improvement study. Can J Neurol Sci. 2025.10.1017/cjn.2025.10491CrossRefGoogle ScholarPubMed